Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to knock out bone metastasis pain

NCT ID NCT06859801

Symptom relief Sponsor: Society of Interventional Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 20, 2026 · Updated 3 times

Summary

This study is looking at whether combining two treatments — a minimally invasive procedure called percutaneous ablation and standard radiation therapy — can better relieve pain from bone cancer that has spread. Researchers will follow 120 people whose pain is not controlled by medication alone. The goal is to see how well the combo works in real-world settings, measuring pain levels, quality of life, and whether it reduces the need for hospital visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Percutaneous ablation (a minimally invasive procedure using heat or cold to destroy nerve and tumor tissue) and palliative radiation therapy (targeted X-rays to shrink tumors and relieve pain)
What this could lead to
If successful, this combination approach could become a standard way to better control pain and reduce complications from bone metastases, improving quality of life for people with advanced cancer.
What could go wrong
This is an observational study, not a controlled experiment, so it cannot prove cause and effect. Results may vary widely among patients, and the procedures carry risks like infection, bleeding, or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with previously untreated symptomatic, high-risk skeletal metastases who are scheduled to be treated with percutaneous ablation combined with palliative RT as part of their normal Standard of Care (SOC).

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Skeletal metastasis with localized pain not controlled medically \[recall within last 24 hours of worst pain ≥ 5 using the BPI\] * 2\. Pain must be from one painful metastatic lesion involving the bone (additional less painful metastatic sites may be present). Extra-osseous extension of disease is allowed (must have some contact with the bone and be causing bone/tumor interface pain) * 3\. Lesions that are at high-risk of skeletal related events defined as follows: * a. Minimum Spinal Instability Neoplastic Score (SINS) score ≥ 7 for lesions involving the spine * b. Pelvic and appendicular lytic lesions with or without cortical breakthrough causing functional/mechanical pain * 4\. Target lesion amenable to percutaneous ablation with image guidance AND RT by specialists' review * 5\. No prior targeted radiation therapy or ablation to the index lesion * 6\. ECOG performance status 0-2 * 7\. Age ≥ 21 years * 8\. Have signed the current approved informed consent form * 9\. Willing and able to answer follow-up Patient Reported Outcomes (PRO) surveys (e.g., PROMIS®, BPI, COST-FACIT, and OMED) for up to 12 months * 10\. Life expectancy \> 3 months Exclusion Criteria: * 1\. Any medical or personal condition that, in the opinion of the site investigator, may potentially compromise the safety or compliance of the patient, or may preclude the patient's successful completion of the clinical trial. * 2\. Target tumor involves a weight-bearing long bone of the lower extremity with the tumor causing \> 50% loss of cortical bone \[MIREL Score ≥ 7\] * 3\. Skeletal lesions with unstable pathologic fractures requiring immediate surgical stabilization * 4\. Concurrent participation in other studies that could affect the primary endpoint * 5\. Target tumor causing clinical or imaging evidence of spinal cord compression

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone cancer metastatic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bone cancer metastatic carcinoma in the bone

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone cancer metastatic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    8 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baptist Health Medical Group

    RECRUITING

    Miami, Florida, 33176, United States

  • Emory University Hospital

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Johns Hopkins Hospital

    RECRUITING

    Baltimore, Maryland, 21287, United States

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Northside Hospital

    RECRUITING

    Atlanta, Georgia, 30342, United States

    Contact Email: •••••@•••••

  • University of California San Diego Moores Cancer Center

    RECRUITING

    San Diego, California, 92093, United States

  • Washington University

    RECRUITING

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.